Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Presence of Psoriasis, Metabolic Syndrome and Their Combination Increases the Serum Levels of CRP and CD5L but Not sCD200R1 and sTLR2 in Participants

D. Holmannova, P. Borsky, C. Andrys, J. Krejsek, E. Cermakova, Z. Fiala, K. Hamakova, T. Svadlakova, H. Parova, V. Rehacek, G. Poctova, L. Borska

. 2022 ; 12 (12) : . [pub] 20221128

Status not-indexed Language English Country Switzerland

Document type Journal Article

Psoriasis and metabolic syndrome (MetS) are chronic inflammatory conditions associated with the dysregulation of immune system reactivity. The inflammatory processes of both diseases have not yet been fully characterized, and the evaluation of proteins/markers that could be involved in their pathogenesis is of great importance. We selected four markers: CRP, sCD200R1, CD5L, and sTLR2; in particular, sCDR2001 has not yet been measured in the context of psoriasis and metabolic syndrome. Material and methods: In the study, 64 controls and 43 patients with psoriasis with or without a metabolic syndrome were enrolled. The levels of selected markers were measured using ELISA kits. Results: CRP levels were significantly higher in psoriasis patients, especially in the subgroup of patients with MetS compared to nonMetS patients (p < 0.01). sCD200R1 and sTLR2 were not significantly different between groups and subgroups; however, CD200R1 levels were slightly higher in both control groups compared to both groups of patients. CD5L levels were significantly higher in patients with MetS compared to nonMets patients (p < 0.02). We also evaluated the correlations between parameters in controls and patients' groups, as well as in subgroups. Correlations between BMI and CRP were found in all groups and subgroups. Other correlations were group- and subgroup-specific. For example, in the patients' group, CD5L correlated with sCD200R1 (p < 0.05) and in MetS controls, with age (p < 0.03). Conclusion: The results show that the presence of systemic inflammation associated with psoriasis and metabolic syndrome and their combination alters the expression of specific molecules, especially CRP and CD5L, which were significantly increased in patients with psoriasis and a metabolic syndrome compared to controls without metabolic syndromes. Correlations between CRP and BMI in all groups suggest that overweight and obesity increase the intensity of inflammation and potentiate CD5L expression. In contrast, levels of molecules that may limit inflammation were not increased in psoriasis and metabolic syndrome subjects (they were non-significantly lower compared with healthy controls), which may reflect the chronic nature of both diseases and the exhaustion of inhibitory mechanisms.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031188
003      
CZ-PrNML
005      
20231116141209.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm12121965 $2 doi
035    __
$a (PubMed)36556186
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Holmannova, Drahomira $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000298659991
245    14
$a The Presence of Psoriasis, Metabolic Syndrome and Their Combination Increases the Serum Levels of CRP and CD5L but Not sCD200R1 and sTLR2 in Participants / $c D. Holmannova, P. Borsky, C. Andrys, J. Krejsek, E. Cermakova, Z. Fiala, K. Hamakova, T. Svadlakova, H. Parova, V. Rehacek, G. Poctova, L. Borska
520    9_
$a Psoriasis and metabolic syndrome (MetS) are chronic inflammatory conditions associated with the dysregulation of immune system reactivity. The inflammatory processes of both diseases have not yet been fully characterized, and the evaluation of proteins/markers that could be involved in their pathogenesis is of great importance. We selected four markers: CRP, sCD200R1, CD5L, and sTLR2; in particular, sCDR2001 has not yet been measured in the context of psoriasis and metabolic syndrome. Material and methods: In the study, 64 controls and 43 patients with psoriasis with or without a metabolic syndrome were enrolled. The levels of selected markers were measured using ELISA kits. Results: CRP levels were significantly higher in psoriasis patients, especially in the subgroup of patients with MetS compared to nonMetS patients (p &lt; 0.01). sCD200R1 and sTLR2 were not significantly different between groups and subgroups; however, CD200R1 levels were slightly higher in both control groups compared to both groups of patients. CD5L levels were significantly higher in patients with MetS compared to nonMets patients (p &lt; 0.02). We also evaluated the correlations between parameters in controls and patients' groups, as well as in subgroups. Correlations between BMI and CRP were found in all groups and subgroups. Other correlations were group- and subgroup-specific. For example, in the patients' group, CD5L correlated with sCD200R1 (p &lt; 0.05) and in MetS controls, with age (p &lt; 0.03). Conclusion: The results show that the presence of systemic inflammation associated with psoriasis and metabolic syndrome and their combination alters the expression of specific molecules, especially CRP and CD5L, which were significantly increased in patients with psoriasis and a metabolic syndrome compared to controls without metabolic syndromes. Correlations between CRP and BMI in all groups suggest that overweight and obesity increase the intensity of inflammation and potentiate CD5L expression. In contrast, levels of molecules that may limit inflammation were not increased in psoriasis and metabolic syndrome subjects (they were non-significantly lower compared with healthy controls), which may reflect the chronic nature of both diseases and the exhaustion of inhibitory mechanisms.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Borsky, Pavel $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000152532808
700    1_
$a Andrys, Ctirad $u Institute of Clinical Immunology and Allergology, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Krejsek, Jan $u Institute of Clinical Immunology and Allergology, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Cermakova, Eva $u Institute of Medical Biophysics, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Fiala, Zdenek $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Hamakova, Kvetoslava $u Clinic of Dermal and Venereal Diseases, University Hospital Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Svadlakova, Tereza $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $u Institute of Clinical Immunology and Allergology, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000215815531
700    1_
$a Párová, Helena $u Institute of Clinical Biochemistry and Diagnostics, University Hospital, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $7 xx0310039
700    1_
$a Rehacek, Vit $u Transfusion Center, University Hospital, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Poctova, Gabriela $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Borska, Lenka $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000285801485
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 12, č. 12 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36556186 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20231116141203 $b ABA008
999    __
$a ok $b bmc $g 1889404 $s 1182521
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 12 $c 12 $e 20221128 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
LZP    __
$a Pubmed-20230119

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...